Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Epilepsia. 2018 May 21;59(6):1166–1176. doi: 10.1111/epi.14196

Figure 4.

Figure 4.

Treatment with GS967 significantly prolongs survival in heterozygous and homozygous mutants. A, Kaplan-Meier survival curves comparing untreated and GS967-treated Scn8aD/+ mice. Treatment was started at 6 weeks of age (first dashed line) and was withdrawn at 6 months (second dashed line). Survival was significantly different between treatment groups (p < 0.001; n = 29–32; Mantel Cox Log Rank test). B, Kaplan-Meier survival curves comparing untreated and GS967-treated Scn8aD/D mice. Treatment was started at 5 days of age (dashed line). Survival difference between treatment groups was significant (p < 0.001; n=6–8; Mantel Cox Log Rank test).